Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI306 in heterozygous familial hypercholesterolemia (China, phase 3)
CTR20192205Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tafolecimab in familial hypercholesterolemia (FH), sponsored by Innovent Biologics. Started Dec 2019; status: completed.
02
Drugs
tafolecimab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on CTR20192205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192205.